Psychedelics Investing Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD
Psychedelics Investing Compass Pathways Establishes Strategic Collaboration with Radial to Innovate Patient Experience and Inform Potential Delivery Model of COMP360
Psychedelics Investing Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression and Clinical Trial Plans for Post-Traumatic Stress Disorder on January 7, 2026, 10:00am ET
Psychedelics Investing Compass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months
Psychedelics Investing NeuroKaire Enters into R&D Collaboration with Compass Pathways to Pioneer Precision Treatments for Depression
Psychedelics Investing Compass Pathways to Announce Third Quarter Financial Results on November 4, 2025
Psychedelics Investing Compass Pathways Announces Publication of Results from Phase 2 Study of COMP360 Psilocybin for Post-Traumatic Stress Disorder
Psychedelics Investing Compass Pathways to Participate in Canaccord Genuity 45th Annual Growth Conference on August 12, 2025 in Boston, MA
Psychedelics Investing Compass Pathways Announces Second Quarter 2025 Financial Results and Business Highlights
Psychedelics Investing Compass Pathways to Announce Second Quarter Financial Results on July 31, 2025
SAGA Metals Announces Additional Assay Results from Drilling at Trapper North, Confirming High-Grade Mineralization at Radar Critical Minerals Project in Labrador
Providence Gold Mines Inc. Announces Final Approval of Reviewable Transaction and The La Dama de Oro Gold Property NI43 101 Report
